MorphoSys AG buy elfe
Start price
20.04.16
/
50%
€50.50
Target price
04.07.16
€65.24
Performance (%)
-22.55%
End price
04.07.16
€39.11
Summary
This prediction ended on 04.07.16 with a price of €39.11. The prediction for MorphoSys AG disappointed with a performance of -22.55%. elfe has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -1.253% | -1.253% | 136.833% | -0.652% |
| iShares Core DAX® | -1.189% | -3.063% | 10.586% | 15.272% |
| iShares Nasdaq 100 | 3.663% | 8.732% | 34.914% | 58.325% |
| iShares Nikkei 225® | -1.422% | -0.414% | 3.883% | 4.190% |
| iShares S&P 500 | 2.182% | 4.907% | 28.279% | 51.241% |
Comments by elfe for this prediction
In the thread Morphosys AG diskutieren
hartmut.kaiser.790 stimmt dem Sentiment von 'Buy' zu
hartmut.kaiser.790 stimmt am 19.04.2016 dem Buy-Gesamtsentiment mit dem Kursziel 65.24€ zu.
(Vom Mitglied beendet)